LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

THE NOVEL GC-A/CGMP ACTIVATING DESIGNER M-ATRIAL NATRIURETIC PEPTIDE POTENTLY REDUCES BLOOD PRESSURE IN A GENETIC MODEL OF HYPERTENSION AND POTENTIATES THE ACTIONS OF FUROSEMIDE

Photo from wikipedia

MANP (ZD100) is a novel best-in-class designer pGC-A/ cGMP activator engineered at the Mayo Clinic for the treatment of resistant hypertension for which there is no FDA approved drug. MANP… Click to show full abstract

MANP (ZD100) is a novel best-in-class designer pGC-A/ cGMP activator engineered at the Mayo Clinic for the treatment of resistant hypertension for which there is no FDA approved drug. MANP has recently been tested in a Phase 1 clinical trial and was blood pressure (BP) lowering, safe and well

Keywords: blood pressure; cgmp; designer; hypertension

Journal Title: Journal of the American College of Cardiology
Year Published: 2019

Link to full text (if available)


Share on Social Media:                               Sign Up to like & get
recommendations!

Related content

More Information              News              Social Media              Video              Recommended



                Click one of the above tabs to view related content.